Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Peloton Interactive Inc (PTON) vs Sanofi SA (SNY) Price & Performance

Peloton Interactive IncTrade

Price performance (Past 24H)

Key statistics

Peloton Interactive Inc vs Sanofi SA — how do they compare? Peloton Interactive Inc trades at $5.01 (market cap $2.16B), while Sanofi SA trades at $40.08 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 44.1× Peloton Interactive Inc's market cap, and Sanofi SA pays a 6.01% dividend while Peloton Interactive Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Peloton Interactive Inc for 37 Days and Sanofi SA for 94 Days on average.

PTONSNY
Market Cap
$2.16B$95.18B
Volume
11,369,4872,995,646
Sector
Consumer CyclicalHealth
52-Week High
$7.86$52.34
52-Week Low
$3.71$39.51
Typical Hold Time
37 Days94 Days
Enterprise Value
$2.66B$114.48B
Dividend Yield
—6.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Peloton Interactive Inc

Peloton (PTON) trades at $4.85, down 0.41% on the day, amid a bearish technical signal and mixed earnings history. The company reported its first full-year net profit in 2026 with a 2.58% net income margin, yet revenue has declined from $3.6B in 2022 to $2.4B in 2026. Positive cash flow trends and a new product launch, including a foldable treadmill, aim to revive growth, but negative shareholder equity and high debt levels persist as concerns.

The outlook hinges on execution of the turnaround strategy; upside exists if new products boost subscriptions, but risks include persistent subscriber declines and high leverage. Analyst consensus is a Buy with a $8.00 price target, suggesting significant potential appreciation from current levels if operational improvements continue.

Sanofi SA

SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.

The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Peloton Interactive Inc

Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.

Read more on PTON →

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY →